Summary of Product Characteristics Translation (UK & EU)

Translating the Summary of Product Characteristics (SmPC) is a critical step in pharmaceutical submissions. Whether you're applying to the MHRA in the UK or the EMA in Europe, a correctly formatted SmPC in the target language is mandatory and any deviation can lead to rejection.

At Tongue Tied, our process is built around regulatory precision, expert-level translation, and UK/EU compliance. With over 30 years in life sciences translation and more than 2,600 clients served, our team ensures your SmPC stays accurate, compliant, and easily maintainable.

What Is an SmPC and Why Does It Matter?

An SmPC is a detailed medical monograph about a medicine, outlining dosage, interactions, contraindications, pharmacokinetics, and prescribing information. Healthcare professionals rely on it as an authoritative reference. It differs from the PIL, which is patient-facing and simplified, while SmPC is clinical and technical.

Regulatory bodies (MHRA in the UK and EMA in the EU) require SmPCs to follow the QRD template (sections 1 to 10) exactly. Using that standard format isn't optional: the MHRA explicitly states that submissions not using the approved Word template will be rejected outright.

UK & EU SmPC Translation Regulations

EMA & QRD Requirements

The EMA maintains a Quality Review of Documents (QRD) template for SmPCs, which must be followed in centralised and hybrid authorisation routes across the EU.

MHRA & UK-Specific Guidelines

The MHRA requires that the SmPC be submitted in the exact format using its official UK SPC template, otherwise, applications are invalid. Even minor template deviations can lead to rejection.

For variations affecting SmPC content, MHRA mandates submission of both clean and annotated versions, using the template format. Omitting updated fragments results in automatic rejection of the variation.

Post-Brexit Considerations

Although EU QRD templates remain largely accepted, applicants must follow UK-specific versions. Separate updates or national templates apply to UK-only product licences, underscoring the need for precise translation aligned with UK MHRA formats.

Key Challenges in SmPC Translation

Translating an SmPC requires more than careful bilingual work, it demands deep subject-matter knowledge and regulatory experience:

Terminology Consistency

Sections include clinical terms like “posology”, “contraindications”, and pharmacodynamics. These must align across languages and client documentation to avoid contradictions or misinterpretation.

Update Management

SmPCs are often revised following new clinical data or regulatory guidance, such as changes in dosing or interactions. EMA and EFPIA recommend immediate update of the SmPC when benefit-risk balance changes.

Template Precision

The structure (section numbering, headings) and phrasing, especially standard boilerplate statements, must exactly follow QRD or MHRA templates. Any deviation, even minor, may lead to submission rejection.

Tongue Tied’s UK‑Compliant SmPC Translation Process

To ensure precision, compliance, and efficiency, here’s how we approach SmPC translation:

1.  Document & Format Review

We confirm source document type and whether the MHRA or EMA version is needed. If a UK variant SmPC format exists, we use it directly.

2.  Terminology & Glossary Alignment

Using EMA standard terminology with QRD statements, MedDRA alignment, and client-specific glossaries ensures consistent translation across SmPC sections.

3.  Translation Memory (TM) Integration

We re-use validated SmPC phrases, such as dosage tables or administration routes, across languages or future updates, reducing time and cost.

4.  Sector-Specialist Translator Assignment

Only translators with pharmaceutical life sciences experience, often former clinicians or regulatory specialists, work on SmPC translation projects.

5.  ISO 17100 Editing & QA

Every translation undergoes secondary review for format, terminology alignment, and accuracy, under ISO 17100-certified QA protocols.

6.  UK In‑Country Review (Optional)

A UK-based expert reviewer checks for template alignment, local phrasing, and MHRA-specific nuances, especially critical for variations or updated sections.

7.  Submission-Ready Final Output

We deliver clean SmPC drafts, future variation fragments, or fully packaged dossier content ready for eCTD submission.

Benefits of Professional SmPC Translation

Regulatory Confidence

You avoid rejection by MHRA/EU authorities for formatting errors or unapproved phrasing.

Terminology Consistency

Standard terms across SmPC, PIL, and dossier ensure clarity and reduce internal compliance risk.

Cost & Time Efficiency

TM reuse, especially across SmPC revisions, reduces translation volume and cost over time.

Streamlined Variation Management

Version control allows only changed fragments to be retranslated, speeding up variation submissions.

Mini Case: UK Pharma SmPC Update Success

A UK pharmaceutical client launched a safety variation affecting posology and side-effect frequencies. We translated the updated section into three EU languages, reused 80% of unchanged text via TM, and delivered the full SmPC within 3 working days.

MHRA accepted the variation without questions or requests for clarification, thanks to precise formatting and terminology alignment.

EEAT & Trust Signals

• Experience: Over 30 years of translating SmPCs and other regulatory documents.

• Expertise: Translators with pharmaceutical and regulatory backgrounds.

• Authoritativeness: ISO 17100-certified workflows; members of ITI and ATC.

• Trustworthiness: Transparent project management, secure data handling, and consistent quality over thousands of MA submissions.

Turnaround & Pricing Estimates

Service Type	Turnaround (Est.)	Cost Saving via TM
Single-language SmPC (≤10,000 words)	3–4 working days	Up to 60%
Multilingual bundle (3–5 languages)	5–7 working days	TM reuse across languages
SmPC update or variation fragment	1–2 days	High — only new segments charged

Quotes are fixed per word or per project. Rush service available upon request.

FAQs (UK & Regulatory Focus)

Can the same translator do both SmPC and PIL? Yes, but best practice is to have specialist translators for each, SmPC translators focus on clinical accuracy, while PIL specialists prioritise plain-language readability.

How are SmPC updates handled? We reuse previous validated translations via TM. Only updated sections require new translation, saving time and cost.

Do I need separate SmPC translations for MHRA and EMA? Often no, if the structure is identical, but UK-only licence holders must use the UK SmPC template wherever specified by MHRA.

Are clinical abbreviations expanded or retained? We retain standard medical abbreviations as per QRD guidelines. Expansion is done only if required or specified in client preference.

Is machine translation ever acceptable? Only for internal drafts. All final translations must be human-reviewed and compliant with regulatory templates.

Let’s Get Your SmPC Translation Right… First Time

Whether you're submitting a new marketing authorisation, preparing variations, or updating safety information, Tongue Tied provides expert SmPC translation that meets UK and EU standards.

📧 sales@ttmltd.com 📞 +44 1606 352 527 Connect with Richard via LinkedIn for expert advice on your next MA submission.